更新于：2024-12-21
Neostigmine Methylsulfate
甲硫酸新斯的明
更新于：2024-12-21
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C13H22N2O6S |
InChIKeyOSZNNLWOYWAHSS-UHFFFAOYSA-M |
CAS号51-60-5 |
关联
118
项与 甲硫酸新斯的明 相关的临床试验Efficacy of Neostigmine as an Adjuvant to Bupivacaine in Ultrasound-guided Transversus Abdominis Plane Block as a Postoperative Analgesia After Caesarean Delivery.
Safety and efficacy of neostigmine as an adjunctive therapy in septic shock : a randomised controlled trial
Prophylactic Intravenous Injection of Neostigmine Plus Atropine Versus Ketorolac on Post-dural Puncture Headache in Patients Undergoing Infraumbilical Surgeries: A Randomized Clinical Trial
100 项与 甲硫酸新斯的明 相关的临床结果
登录后查看更多信息
100 项与 甲硫酸新斯的明 相关的转化医学
登录后查看更多信息
100 项与 甲硫酸新斯的明 相关的专利（医药）
登录后查看更多信息
4,320
项与 甲硫酸新斯的明 相关的文献（医药）2025-02-01JOURNAL OF PHARMACY PRACTICE
A Case of Delayed and Persistent Carbamazepine Overdose Treated With Hemodialysis, Plasmapheresis, and Neostigmine
Article
作者: Ondiveeran, Hari K ; Walsh, Liam D ; Cameron-Coffill, Kayla M
Carbamazepine is utilized for various indications. Due to its pharmacokinetic profile and drug properties, toxicity can be delayed and persistent despite supportive care. We report a severe case of intentional carbamazepine toxicity in a carbamazepine naive individual mimicking brain death that was not diagnosed until three days after consumption of carbamazepine when the patient was comatose. Symptoms of overdose persisted for several days despite attempted treatment with activated charcoal and whole bowel irrigation, hemodialysis, and plasmapheresis. Symptoms only began to improve with bowel evacuation as a result of administration of neostigmine intravenously plus hemodialysis and plasmapheresis additionally. Despite previous literature that reported success with hemodialysis and/or plasmapheresis we did not find either to be overly effective in our case possibly due to lack of ability to perform multidose activated charcoal and whole bowel irrigation. To our knowledge this is one of the few cases of carbamazepine overdose utilizing both hemodialysis and plasmapheresis but without activated charcoal and the only case report in which neostigmine was administered as an attempt to remove drug via the gastrointestinal tract with success.
2025-01-01Anesthesia and analgesia
Factors Associated With Decision to Use and Dosing of Sugammadex in Children: A Retrospective Cross-Sectional Observational Study
Article
作者: Mentz, Graciela ; Nause-Osthoff, Rebecca ; Cassidy, Ruth ; Wade, Meridith ; Brown, Sydney E.S. ; Colquhoun, Douglas A. ; Liu, Xinyue ; Kheterpal, Sachin ; Zhong, Wenjun ; DiBello, Julia
BACKGROUND::
Sugammadex was initially approved for reversal of neuromuscular blockade in adults in the United States in 2015. Limited data suggest sugammadex is widely used in pediatric anesthesia practice however the factors influencing use are not known. We explore patient, surgical, and institutional factors associated with the decision to use sugammadex versus neostigmine or no reversal, and the decision to use 2 mg/kg vs 4 mg/kg dosing.
METHODS::
Using data from the Multicenter Perioperative Outcomes Group (MPOG) database, an EHR-derived registry, we conducted a retrospective cross-sectional study. Eligible cases were performed between January 1, 2016 and December 31, 2020, for children 0 to 17 years at US hospitals. Cases involved general anesthesia with endotracheal intubation and administration of rocuronium or vecuronium. Using generalized linear mixed models with institution and anesthesiologist-specific random intercepts, we measured the importance of a variety of patient, clinician, institution, anesthetic, and surgical risk factors in the decision to use sugammadex versus neostigmine, and the decision to use a 2 mg/kg vs 4 mg/kg dose. We then used intraclass correlation statistics to evaluate the proportion of variance contributed by institution and anesthesiologist specifically.
RESULTS::
There were 97,654 eligible anesthetics across 30 institutions. Of these 47.1% received sugammadex, 43.1% received neostigmine, and 9.8% received no reversal agent. Variability in the choice to use sugammadex was attributable primarily to institution (40.4%) and attending anesthesiologist (27.1%). Factors associated with sugammadex use (compared to neostigmine) include time from first institutional use of sugammadex (odds ratio [OR], 1.08, 95% confidence interval [CI], 1.08–1.09, per month, P < .001), younger patient age groups (0–27 days OR, 2.59 [2.00–3.34], P < .001; 28 days–1 year OR, 2.72 [2.16–3.43], P < .001 vs 12–17 years), increased American Society of Anesthesiologists [ASA] physical status (ASA III: OR, 1.32 [1.23–1.42], P < .001 ASA IV OR, 1.71 [1.46–2.00], P < .001 vs ASA I), neuromuscular disease (OR, 1.14 (1.04–1.26], P = .006), cardiac surgery (OR, 1.76 [1.40–2.22], P < .001), dose of neuromuscular blockade within the hour before reversal (>2 ED95s/kg OR, 4.58 (4.14–5.07], P < .001 vs none), and shorter case duration (case duration <60 minutes OR, 2.06 [1.75–2.43], P < .001 vs >300 minutes).
CONCLUSIONS::
Variation in sugammadex use was primarily explained by institution and attending anesthesiologist. Patient factors associated with the decision to use sugammadex included younger age, higher doses of neuromuscular blocking agents, and increased medical complexity.
2025-01-01BEHAVIOURAL BRAIN RESEARCH
Central cholinergic transmission modulates endocannabinoid-induced marble-burying behavior in mice
Article
作者: Rao, Laxmi ; Patel, Richa ; Jain, Nishant Sudhir ; Patel, Chhatrapal ; Kesharwani, Anuradha
Central cholinergic system and endocannabinoid, anandamide exhibits anti-compulsive-like behavior in mice. However, the role of the central cholinergic system in the anandamide-induced anti-compulsive-like behavior is still unexplored. Therefore, the present study assessed the role of central cholinergic transmission in the anandamide-induced anti-compulsive activity using a marble-burying behavior (MBB) model in mice. The modulation in the anandamide-induced effect on MBB was evaluated using mice with altered central cholinergic transmission achieved by pretreatment (i.c.v.) with various cholinergic agents like acetylcholine (ACh), acetylcholinesterase inhibitor (AChEI), neostigmine, nicotine, mAChR antagonist, atropine, and nAChR antagonist, mecamylamine. The influence of anandamide treatment on the brain AChE activity was also evaluated. The results revealed that i.c.v. injection of anandamide (10, 20 µg/mouse, i.c.v.) dose-dependently reduced MBB in mice. Moreover, anandamide in all the tested doses inhibited the brain AChE activity indicating the role of an enhanced central cholinergic transmission in its anti-compulsive-like effect . Furthermore, the anti-compulsive-like effect of anandamide (20 µg/mouse, i.c.v.) was found to be enhanced in mice centrally pre-treated with, ACh (0.1 µg/mouse, i.c.v.) or AChEI, neostigmine (0.3 µg/mouse, i.c.v.). In addition, the anandamide-induced anti-compulsive-like effect was significantly increased in mice pre-treated with a low dose of nicotine (0.1 µg/mouse, i.c.v.) while, it was attenuated by the higher dose of nicotine (2 µg/mouse, i.c.v.). On the other hand, the anandamide (20 µg/mouse, i.c.v.) induced anti-compulsive-like effect was found to be diminished in mice pre-treated with mAChR antagonist, atropine (0.1, 0.5 µg/mouse, i.c.v.) and pre-injection of nAChR antagonist, mecamylamine (0.1, 0.5 µg/mouse, i.c.v.) potentiated the anandamide induced anti-compulsive-like response in mice. Thus, the present investigation delineates the modulatory role of an enhanced central cholinergic transmission in the anandamide-induced anti-compulsive-like behavior in mice by inhibition of brain AChE or via muscarinic and nicotinic receptors mediated mechanism.
100 项与 甲硫酸新斯的明 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经肌肉阻滞逆转 | 日本 | 2001-03-13 | |
| 胃肠胀气 | 中国 | 1995-01-01 | |
| 尿潴留 | 中国 | 1995-01-01 | |
| 呼吸困难 | 日本 | 1936-10-01 | |
| 排尿困难 | 日本 | 1936-10-01 | |
| 重症肌无力 | 日本 | 1936-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 235 | (Neostigmine) | 襯積築繭願鏇襯製獵廠(襯繭鬱顧觸繭繭襯範鹹) = 製顧壓衊鏇蓋觸鑰構遞 膚鹹積壓積積觸網醖網 (鬱鹹醖觸構繭憲廠範壓, 顧齋鏇膚製壓鑰衊網鬱 ~ 顧齋醖壓構壓醖顧選願) 更多 | - | 2024-10-09 | ||
(Sugammadex) | 襯積築繭願鏇襯製獵廠(襯繭鬱顧觸繭繭襯範鹹) = 觸鑰願觸範襯遞選觸壓 膚鹹積壓積積觸網醖網 (鬱鹹醖觸構繭憲廠範壓, 襯簾製艱獵夢齋鬱獵壓 ~ 齋糧夢夢餘襯膚鹽願憲) 更多 | ||||||
N/A | - | 網製憲壓膚願蓋壓製築(襯選廠獵願選窪鬱鹽艱): RR = 0.37 (95% CI, 0.26 ~ 0.54) 更多 | - | 2024-05-18 | |||
(Decompressive Colonoscopy) | |||||||
N/A | - | 夢窪窪願襯選遞遞糧鹽(窪襯築積衊繭鏇遞襯選): RR = 0.37 (95% CI, 0.26 ~ 0.54) 更多 | - | 2024-05-18 | |||
(Decompressive Colonoscopy) | |||||||
N/A | - | 醖淵餘衊觸獵製選淵鹹(糧艱淵襯選範膚糧構夢): RR = 0.37 (95% CI, 0.26 ~ 0.54) 更多 | - | 2024-05-18 | |||
(Decompressive colonoscopy) | |||||||
N/A | - | 鏇餘廠蓋艱鑰鏇鹽範願(範鹽願糧餘蓋鑰鏇艱蓋): RR = 0.37 (95% CI, 0.26 ~ 0.54) 更多 | - | 2024-05-18 | |||
(Decompressive Colonoscopy) | |||||||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 網艱鹹鹽餘獵築觸夢鑰(窪壓遞網遞範鏇鹽製廠) = 蓋壓觸願鹽積壓鬱齋遞 鬱鹽簾壓獵窪遞餘蓋範 (選壓鑰獵繭淵餘觸築製, 築構網鬱艱範壓構築遞 ~ 願獵艱觸構艱糧淵鏇積) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 網艱鹹鹽餘獵築觸夢鑰(窪壓遞網遞範鏇鹽製廠) = 積範淵襯廠壓鑰觸醖鹽 鬱鹽簾壓獵窪遞餘蓋範 (選壓鑰獵繭淵餘觸築製, 廠餘製鹹衊鹹願範襯餘 ~ 廠積餘窪齋獵糧窪範壓) 更多 | ||||||
临床2期 | 49 | (Cisatracurium + Neostigmine) | 鏇積範夢鬱觸觸艱餘簾(襯範選鹽膚築壓顧獵範) = 鏇範築願鹽鏇繭構繭壓 簾憲願範憲憲憲選鹹構 (築製繭襯糧蓋築糧構鏇, 範膚襯獵淵膚願齋蓋襯 ~ 艱淵鹹鬱廠齋顧願築糧) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 鏇積範夢鬱觸觸艱餘簾(襯範選鹽膚築壓顧獵範) = 衊襯製願築範範衊構顧 簾憲願範憲憲憲選鹹構 (築製繭襯糧蓋築糧構鏇, 壓遞顧範窪窪遞鬱壓艱 ~ 積鹹觸窪艱鹹鬱憲築鑰) 更多 | ||||||
临床4期 | 200 | 鏇夢選夢餘鑰膚繭壓顧(鬱壓艱範鏇憲蓋蓋遞選) = 網糧襯範選觸鏇餘廠遞 襯鹹淵廠築淵觸獵衊醖 (壓襯窪範艱顧齋鏇願構, 餘築齋糧網膚鑰醖鏇膚 ~ 選憲鑰簾壓鏇齋網齋艱) 更多 | - | 2022-11-02 | |||
临床2期 | 167 | standard therapy+Neostigmine | 鹽簾觸衊糧顧齋繭壓憲(簾觸積襯製鹽網憲鹽糧) = 蓋築簾鬱製鹹淵壓鬱簾 遞壓壓築淵餘繭觸鏇鏇 (構夢願憲獵襯構觸艱鏇 ) | 积极 | 2022-03-07 | ||
standard therapy+0.9% saline | 鹽簾觸衊糧顧齋繭壓憲(簾觸積襯製鹽網憲鹽糧) = 獵鏇製積艱繭願鹹窪顧 遞壓壓築淵餘繭觸鏇鏇 (構夢願憲獵襯構觸艱鏇 ) | ||||||
临床2期 | 80 | 獵遞淵製襯製繭觸衊廠(繭窪遞積築夢壓襯鬱齋) = 遞廠範選窪願壓餘簾獵 願糧蓋廠淵製膚壓範鏇 (艱構艱獵範鏇餘廠遞餘, [-28.4 ~ -4.7]) | 积极 | 2022-03-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用